Crude and adjusted ORs for antiepileptic drug (AED) type and maternal epilepsy type
| Group | Total | NDDs | No NDDs | Incidence rate (%) | Unadjusted OR | Adjusted OR* (95% CI) | p Value |
|---|---|---|---|---|---|---|---|
| Control | 214 | 4 | 210 | 1.87 | Reference group | Reference group | – |
| No Medication | 26 | 0 | 26 | 0.00 | – | – | – |
| VPA | 50 | 6 | 44 | 12.00 | 7.16 | 6.05 (1.65 to 24.53) | 0.007 |
| CBZ | 50 | 1 | 49 | 2.00 | 1.07 | 1.09 (0.06 to 7.39) | 0.9 |
| LTG | 30 | 2 | 28 | 6.67 | 3.75 | 4.06 (0.55 to 22.20) | 0.1 |
| Other Monotherapy | 14 | 2 | 12 | 14.29 | 8.75 | 8.17 (1.09 to 49.40) | 0.02 |
| Polytherapy with VPA | 20 | 3 | 17 | 15.00 | 9.26 | 9.97 (1.82 to 49.40) | 0.005 |
| Other Polytherapy | 11 | 1 | 10 | 9.09 | 5.25 | 4.95 (0.25 to 40.45) | 0.2 |
| Focal | 108 | 9 | 99 | 8.33 | 4.77 | 4.76 (1.42 to 15.94) | 0.01 |
| Idiopathic Generalised | 65 | 4 | 61 | 6.15 | 3.44 | 3.15 (0.76 to 13.09) | 0.1 |
| Unclassified | 28 | 2 | 26 | 7.14 | 4.04 | 3.74 (0.65 to 21.67) | 0.1 |
Note: significant results are highlighted in bold.
*Separate regression models were created for AED and maternal epilepsy type regressions due to the limited numbers of cases per drug by maternal epilepsy type.
CBZ, carbamazepine; VPA, valproate.